A randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of atorvastatin in patients with clinically isolated syndrome and high risk of conversion to multiple sclerosis.

Trial Profile

A randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of atorvastatin in patients with clinically isolated syndrome and high risk of conversion to multiple sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms STAYCIS
  • Most Recent Events

    • 17 Apr 2010 Primary endpoint results presented at the 62nd Annual Meeting of the American Academy of Neurology
    • 17 Apr 2010 Primary endpoint 'Number of multiple sclerosis lesions' has not been met.
    • 17 Apr 2010 Primary endpoint 'Symptom exacerbation rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top